- Surgical revascularization for Moyamoya disease in the United States: A cost-effectiveness analysis
-
Wali AR, Santiago-Dieppa DR, Srinivas S, Brandel MG, Steinberg JA, Rennert RC, Mandeville R, Murphy JD, Olson S, Pannell JS, Khalessi AA
- KMID: 2514333
- J Cerebrovasc Endovasc Neurosurg.
- 2021 Mar;23(1):6-15.
- doi: 10.7461/jcen.2021.E2020.07.002
Objective: Moyamoya disease (MMD) is a vasculopathy of the internal carotid arteries with ischemic and hemorrhagic sequelae. Surgical revascularization confers upfront peri-procedural risk and costs in exchange for long-term protective... -
- CITED
-
- Close
- SHARE
-
- Close
- Antiplatelet therapy within 24 hoursof tPA: lessons learned from patientsrequiring combined thrombectomyand stenting for acute ischemic stroke
-
Brandel MG, Elsawaf Y, Rennert RC, Steinberg JA, Santiago-Dieppa DR, Wali AR, Olson SE, Pannell JS, Khalessi AA
- KMID: 2500067
- J Cerebrovasc Endovasc Neurosurg.
- 2020 Mar;22(1):1-7.
- doi: 10.7461/jcen.2020.22.1.1
Objective: Although stroke guidelines recommend antiplatelets be started 24 hours after tissue plasminogen activator (tPA), select mechanical thrombectomy (MT) patients with luminal irregularities or underlying intracranial atherosclerotic disease may benefit from earlier antiplatelet... -
- CITED
-
- Close
- SHARE
-
- Close
